Showing 1931-1940 of 2105 results for "".
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Prescription Patterns in Multiple Sclerosis Changinghttps://practicalneurology.com/news/prescription-patterns-in-multiple-sclerosis-changing/2469504/Neurologists are prescribing more oral disease-modifying therapy (DMT) for initial treatment of multiple sclerosis (MS) than ever. Out of 1,018 individuals with multiple sclerosis (MS) in a 3-month period, close to half received an oral DMT as their first treatment. Only 4 years ago, the proporti
- Lenalidomide for Potential Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/lenalidomide-for-potential-treatment-of-alzheimer-disease-1/2469487/New phase 2 studies are being initiated for lenalidomide (Revlimid; Bristol Myers Squibb, New York, NY), which is an analogue of thalidomide. Eligible participants include those with early-stage Alzheimer disease (AD)/ mild cognitive impairment (MCI). The first study will evaluate the long-term u
- New Genetic Tests Available for Hereditary Ataxiashttps://practicalneurology.com/news/new-genetic-tests-available-for-hereditary-ataxias/2469486/Several genetic tests, including repeat-expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxia have been newly made available by GeneDx (Gaithersberg, MD). The repeat-expansion analysis may be done concurrently with single nucleotide va
- Clinical Trial of Neuromodulation for Alzheimer Disease and Mild Cognitive Impairment Expandedhttps://practicalneurology.com/news/clinical-trial-of-neuromodulation-for-alzheimer-disease-and-mild-cognitive-impairment-expanded/2469463/Clinical trials of transcranial direct current stimulation (tDCS)(ElectraRx; Soterix Medical, New York, NY) for potential treatment of Alzheimer disease (AD), mild cognitive impairment (MCI), and age-related cognitive decline have been expanded. The study of the proprietary neurostimulation devic
- Long-Term Freedom from Seizure With Perampanel Treatmenthttps://practicalneurology.com/news/long-term-freedom-from-seizure-with-perampanel-treatment/2469455/In a post-hoc analysis, of the phase 3 FREEDOM study (NCT03201900), 62.5% of individuals treated with 4 to 8 mg/day of perampanel (Fycompa, Eisai Inc, Woodcliff Lake, NJ) achieved seizure freedom for 1 year. Participants in the study w
- Anxiety and Depression Prevalence in Children and Adolescents With Epilepsyhttps://practicalneurology.com/news/anxiety-and-depression-prevalence-in-children-and-adolescents-with-epilepsy/2469453/According to research presented virtually at American Epilepsy Society AES2020, children and adolescents with epilepsy are more likely to have anxiety and depression, including suicidal thinking, then previously considered. In a study of 119 children age 9 to 18 years, none of who
- Laser Thermal Ablation Therapy Brings Seizure Freedom to 54% of Children Treatedhttps://practicalneurology.com/news/laser-thermal-ablation-therapy-brings-seizure-freedom-to-54-of-children-treated/2469450/A new study being presented virtually at American Epilepsy Society AES2020 showed MRI-guided laser interstitial thermal therapy (MR-LITT) in children with medically refractory epilepsy, achieved seizure freedom for 54% 1 year after the procedure. Children treated (n=182) were age 14 months of age
- Vatiquinone Phase 3 Trial Initiated for Potential Treatment of Friedreich Ataxiahttps://practicalneurology.com/news/vatiquinone-phase-3-trial-initiated-for-potential-treatment-of-friedreich-ataxia/2469445/The registration-directed phase 3 MOVE-FA study (NCT04577352) evaluating vatiquinone (PTC743; PTC Therapeutics, South Plainfield, NJ) in children and young adults with Friedreich ataxia (FA) has b